web analytics

Scientific program

Thursday, October 26, 2017

 14:00 – 14:15 Congress Opening Hall A
 14:15 – 15:30 Plenary Session 1:
Breast cancer genetics
 14:15 – 14:45
14:15
14:30
Debate: That liberal use of genetic testing should be encouraged
Yes: Arlene Chan, Australia
No: Nick Wilcken, Australia
 14:45 – 15:05 Management of genetic mutation carriers
Ava Kwong, Hong Kong
 15:05 – 15:30 Panel discussion: Controversial cases
Arlene Chan, Australia
Nick Wilcken, Australia
Ava Kwong, Hong Kong
15:30 – 17:00 Plenary Session 2:
Neoadjuvant therapy
15:30 – 16:05
15:30
15:42
15:54
Debate: That NAST choice should be based on more TN stage rather than on biological subtype
TN Stage: Louis Chow, Hong Kong
Biological subtype: Stacy Moulder,
USA
Discussion
16:05 – 16:40
16:05
16:17
16:29
Debate: That all patients with positive nodes pre-neoadjuvant therapy should have axillary dissection as part of cancer surgery
Yes:  Ian Campbell, New Zealand
No: Abigail Suzanne Caudle, USA
Discussion
16:40 – 17:00 The role of oral 5FU in the adjuvant setting after primary systemic therapy
Masakazu Toi, Japan
17:30 – 19:00 Industry Symposium:
The 21 Gene Assay: The Evidence in 2017

Friday, October 27, 2017

08:00 – 09:00 Morning Industry Symposium:

 

09:00 – 10:00 Plenary Session 3:
Immunotherapy/TNBC
 09:00 – 09:30 PARP inhibitors: Where do they fit in breast cancer management?
Wolfgang Janni, Germany
09:30 – 10:00 Is immunotherapy likely to be a game-changer in breast cancer?
Sunil Verma, Canada
10:00 – 11:00 Plenary Session 4:
Adjuvant endocrine therapy
10:00 – 10:30
10:00
10:15
Debate: That OFS + AI should be standard of care in young patients with high-risk HR+ve breast cancer
Yes: Wolfgang Janni, Germany
No: Richard de Boer,
Australia
10:30 – 11:00 Duration of/choice of adjuvant endocrine therapy
Nick Wilcken, Australia
11:30 – 12:30 Parallel Session 5:
Imaging
Chairperson: Chiun-Sheng Huang, Taiwan
11:30 – 11:50 Breast ultrasound in cancer screening: The J-start experience
Akihiko Suzuki, Japan
11:50 – 12:10 Screening technologies: One size does not fit all
Elizabeth Morris, USA
12:10 – 12:30 What is the best way to assess response to neoadjuvant therapy?
Naoki Hayashi, Japan
11:30 – 12:30 Parallel Session 6:
Free Papers
12:45 – 13:45 Luncheon Industry Symposium:

 

12:45 – 13:45 Luncheon Industry Symposium:
Current situation and future perspective of HBOC treatment in Japan
14:00 – 15:30 Plenary Session 7:
Locoregional therapy
Chairperson Won Shik Han, Korea
14:00 – 14:20 What is the optimal way to achieve clear margins in BCS?
Alastair Thompson, USA
14:20 – 14:55
14:20
14:32
14:44
Debate: That regional nodal radiotherapy is required in all early stage node positive breast cancer
Yes: Sanjoy Chatterjee, India
No: Louis Chow,
Hong Kong
Discussion
14:55 – 15:30
14:55
15:07
15:19
Debate: That surgical axillary assessment should be routine for all patients with invasive breast cancer
Yes: Koichiro Tsugawa, Japan
No: Abigail Suzanne Caudle, USA
Discussion
 15:30 – 16:30 Parallel Session 8:
DCIS
Chairperson Jin Zhang, China
15:30 – 15:50 Biology of DCIS
Sunil R. Lakhani, Australia
15:50 – 16:30
15:50
16:05
16:20
Debate: That active surveillance for low risk DCIS should be considered
Yes: Alastair Thompson, USA
No: Raghu Ram, India
Discussion
17:00 – 18:30 Industry Symposium:

 

15:30 – 16:30 Parallel Session 9:
Her2+ve
15:30 – 16:00
15:30
15:40
15:50
Debate: That neratanib should be offer as a standard of care in adjuvant therapy of Her2+ve breast cancer
Yes: Arlene Chan, Australia
No: Sunil Verma, Canada
Discussion
16:00 – 16:30 State of the art in metastatic Her2+ early breast cancer
Javier Cortes, Spain

Saturday, October 28, 2017

08:30 – 09:30 Morning Industry Symposium:

 

08:30 – 09:30 Morning Industry Symposium:

 

09:45 – 10:45 Parallel Session 10:
Reconstruction/radiation
09:45 – 10:15
09:45
09:55
10:05
Debate: That chest wall radiotherapy prior to mastectomy and reconstruction is a good option
Yes: Sanjoy Chatterjee, India
No: Ian Campbell,
New Zealand
Discussion
10:15 – 10:45
10:15
10:30
Debate: That fear and ignorance drive the rise in contralateral prophylactic mastectomy
Yes: Hideko Yamauchi, Japan
No: Raghu Ram, India
09:45 – 10:45 Parallel Session 11:
Free Papers
11:15 – 12:45 Plenary Session 12:
Breast cancer 2022
Chairpersons Bruce Mann, Australia
Seigo Nakamura, Japan
How will breast cancer management change by 2022 for the:
11:15-11:30 Pathologist
Sunil R. Lakhani, Australia
11:30-11:45 Radiologist
Elizabeth Morris, USA
11:45-12:00 Surgeon
Seigo Nakamura, Japan
12:00-12:15 Medical oncologist
Stacy Moulder, USA
12:15-12:30 Radiation oncologist
Sanjoy Chatterjee, India
12:30-12:45 Discussion
12:45 – 13:00 Congress wrap-up and award presentation
13:15 – 14:15 Luncheon Industry Symposium:

 

13:15 – 14:15 Luncheon Industry Symposium:

 

14:30 – 18:25 Young doctors’ summit in Asia
14:30 – 15:10 Debate 1: Management of ductal carcinoma in situ: Is surgical resection needed or not?
15:15 – 15:55 Debate 2: Imaging modality for dense breast. Which is more effective: ultrasonography or tomosynthesis?
16:15 – 16:55 Debate 3: Position of gene testing; BRCA mutation test should be used as companion
17:00 – 17:40 Debate 4: Predictive marker for hormone-receptor positive HER2 negative patients; Which do you use for your patients in the clinical management in selecting adjuvant therapy, multigene tests or IHC4?
17:45 – 18:25 Debate 5: Treatment of hormone-refractory metastatic breast cancer; Which is more effective:  CDK4/6 inhibitor or mTOR inhibitor?